Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Characterization of TDP-43 role on SORT1 dysfunction and PGRN altered signal in neurodegenerative diseases.

FY 2011-12

Summary
Amyotrophic lateral sclerosis (ALS) is the most common of motor neuron diseases (MND), while frontotemporal lobar degeneration (FTLD) is the second most common cause of early-onset dementia. Interestingly, up to 50% of ALS patients do develop some sort of cognitive impairments. In 2006, the TDP-43 protein was found to be an important constituent of aggregates in neurons of MND -FTLD patients, which confirmed the common pathological pathway involved in the two conditions. Mutations in the TARDBP gene encoding the TDP-43 protein have been identified in both ALS and FTLD patients. Neurons of these patients display a nuclear clearing and cytoplasmic sequestration of the normal cellular TDP-43 protein. Lately, it has been found that depletion of TDP-43 in the mouse adult brain modifies the expression of the GRN gene which encodes the progranulin protein. Precisely, mutations in GRN are found in about 5-10% of all FTLD patients and cause TDP-43 cytoplasmic inclusions. It was also demonstrated that depletion of TDP-43 alters the splicing of SORT1 encoding sortilin, a receptor of progranulin. We hypothesize that abnormalities in TDP-43 cause SORT1 dysfunction and consequently alter PGRN signaling. This, in turn, is expected to accelerate TDP-43 pathology and the development of neurodegeneration. Considering this, the aim of the study is to understand the role and interactions of TDP-43, PGRN and SORT1 in the common pathway leading to MND-FTLD. The critical goal is to identify the proper therapeutic targets to eventually develop drugs or treatments that will stop and ultimately prevent neurodegeneration.
Program
CIHR Fellowship
Location
Florida, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
242681
Name
Belzil Veronique
Region
Florida
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of TDP-43 role on SORT1 dysfunction and PGRN altered signal in neurodegenerative diseases.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adenoviral Approach; Cell Transfection; Co-Immunoprecipitation; Gene Expression; Gene Knocked-Down; Gene Splicing; Gst-Pull Down; Molecular Biology; Mouse Model; Protein Binding
Abstract
Amyotrophic lateral sclerosis (ALS) is the most common of motor neuron diseases (MND), while frontotemporal lobar degeneration (FTLD) is the second most common cause of early-onset dementia. Interestingly, up to 50% of ALS patients do develop some sort of cognitive impairments. In 2006, the TDP-43 protein was found to be an important constituent of aggregates in neurons of MND -FTLD patients, which confirmed the common pathological pathway involved in the two conditions. Mutations in the TARDBP gene encoding the TDP-43 protein have been identified in both ALS and FTLD patients. Neurons of these patients display a nuclear clearing and cytoplasmic sequestration of the normal cellular TDP-43 protein. Lately, it has been found that depletion of TDP-43 in the mouse adult brain modifies the expression of the GRN gene which encodes the progranulin protein. Precisely, mutations in GRN are found in about 5-10% of all FTLD patients and cause TDP-43 cytoplasmic inclusions. It was also demonstrated that depletion of TDP-43 alters the splicing of SORT1 encoding sortilin, a receptor of progranulin. We hypothesize that abnormalities in TDP-43 cause SORT1 dysfunction and consequently alter PGRN signaling. This, in turn, is expected to accelerate TDP-43 pathology and the development of neurodegeneration. Considering this, the aim of the study is to understand the role and interactions of TDP-43, PGRN and SORT1 in the common pathway leading to MND-FTLD. The critical goal is to identify the proper therapeutic targets to eventually develop drugs or treatments that will stop and ultimately prevent neurodegeneration.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Belzil, Veronique
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~